What Researchers Did
Researchers quantified the effect of hyperbaric oxygen therapy (HBOT) as an adjuvant to daptomycin and rifampicin treatment in a murine model of Staphylococcus aureus implant-associated osteomyelitis.
What They Found
In a study involving 80 mice, hyperbaric oxygen therapy (HBOT) did not improve the treatment outcomes of daptomycin and rifampicin combination therapy against implant-associated osteomyelitis. The addition of daily intermittent HBOT (304 kPa for 60 min) showed no enhanced effect compared to antibiotics alone.
What This Means for Canadian Patients
Canadian patients with implant-associated osteomyelitis should not expect additional benefit from hyperbaric oxygen therapy when combined with daptomycin and rifampicin. Standard antibiotic regimens remain the primary treatment strategy for these challenging infections.
Canadian Relevance
This study has no direct Canadian connection, as it was not conducted in Canada nor involved Canadian participants or institutions.
Study Limitations
A primary limitation is that the findings are based on a murine model, which may not directly translate to human clinical outcomes.